Efeito da Quitosana-Fe(III) reticulada sobre a calcificação vascular em um modelo de uremia
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora
DOI
Abstract
Introduction: Chronic Kidney Disease (CKD) causes changes in the concentrations
of phosphorus, calcium, vitamin D and parathyroid hormone. Cross-linked Iron(III)
Chitosan (QST-Fe(III)R) is a phosphorus binder, with properties of reducing the
hyperphosphatemia, the main inducer of vascular calcification (VC) in CKD. This
polymer derived from chitin showed chelating action on phosphorus in vitro and in
vivo. Objective: To evaluate the phosphorus chelating action of QST-Fe(III)R and its
effect on VC in adenine-induced uremic rats. Methods: Normal and uremic rats,
induced by adenine feeding (0.75% - 4 weeks and 0.10% - 3 weeks) and
phosphorous 1%, were divided into 4 groups and treated daily with distilled water
(10ml/kg/day); QST-Fe(III)R 30mg/kg/day; CaCO3 500mg/kg/day and sevelamer
hydrochloride (Cl-Sev) 500mg/kg/day, for 4 weeks. Biochemical parameters were
measured at the fourth and seventh week: creatinine (Cr), phosphorus (P) and serum
calcium (Ca), alkaline phosphatase (FA), PTH and FGF23. The Ca content of the
abdominal aortic fragments was quantified and expressed as mg/g of aortic tissue.
We evaluated vascular changes in the aortic arch and calcium deposition. Specific
antibodies used to identify the expression of angiotensin II (AngioII) and alphasmooth
muscle actin (α-actin) by immunohistochemical technique, in fragments of
abdominal aorta at seventh week. Results: In uremic groups, we observed reduced
kidney function and a maximum creatinine in the fourth week. The treatments did not
alter CKD progression. The CKD group showed 35% higher phosphorus, compared
to the control group. All treatments reduced approximately in 20% the serum
phosphorus, and reduced the FeP (reduction of 20% to 30%). Treatments with QTSFe(
III)R and CaCO3 were effective in reducing PTH and FA of uremic rats. We
believe that treatment with Cl-Sev has not been effective due to methodological
problems during drug administration. The CKD group presented aortic calcium
content 80% higher than the control group and the QTS-Fe(III)R reduced the calcium
content in the aorta, more than all other treatments. Compared to the control group,
the QTS-Fe(III)R promotes the reduction expression of AngioII in aortic intima. The
treatments did not show benefits over the media layer integrity when evaluating the
α-actin expression. Conclusions: The experimental model showed important and
sustained loss of renal function. The QTS-Fe(III)R showed efficiency similar to others
phosporus binders already used in clinical practice and reduced the calcium content
in the aorta.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
